Kirhan Ozgurdal
Overview
Explore the profile of Kirhan Ozgurdal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singal A, Ozgurdal K, Fan X, Vassilev Z, Pan X, Multani J, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067235
Real-world (RW) evidence is needed to evaluate atezolizumab plus bevacizumab (atezo + bev) utilization for hepatocellular carcinoma (HCC) in clinical practice. This retrospective cohort study used administrative claims databases to...
2.
Merle P, Kudo M, Krotneva S, Ozgurdal K, Su Y, Proskorovsky I
Liver Cancer
. 2023 Jun;
12(2):145-155.
PMID: 37325487
Introduction: The tyrosine kinase inhibitors regorafenib and cabozantinib remain the mainstay in second-line treatment of advanced hepatocellular carcinoma (HCC). There is currently no clear evidence of superiority in efficacy or...
3.
Brose M, Smit J, Lin C, Tori M, Bowles D, Worden F, et al.
Thyroid
. 2022 Aug;
32(9):1059-1068.
PMID: 35950621
Sorafenib and lenvatinib are multikinase inhibitors (MKIs) approved for patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). There is no consensus on when to initiate MKI treatment. The objective...
4.
Dane F, Ozgurdal K, Yalcin S, Benekli M, Aykan N, Yucel I, et al.
BMJ Open
. 2020 Mar;
10(3):e027665.
PMID: 32220908
Objectives: Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD...